How effective is dabigatran etexilate capsules (Pradaxa)?

Dabigatran etexilate capsule (Pradaxa) is a direct thrombin inhibitor, mainly used for anticoagulation therapy to prevent and treat thrombosis-related diseases, such as non-valvular atrial fibrillation, deep vein thrombosis and pulmonary embolism. Its therapeutic effect is mainly reflected in effectively preventing thrombosis while minimizing the risk of bleeding. The following is a discussion of the therapeutic effect of dabigatran etexilate capsules based on clinical experimental data.

1. Stroke prevention in non-valvular atrial fibrillation: Clinical experimental data show that dabigatran etexilate capsules have similar or even better stroke prevention effects compared to traditional anticoagulants such as warfarin in patients with non-valvular atrial fibrillation. The RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial is a large-scale clinical trial involving 18,113 patients with nonvalvular atrial fibrillation. The trial results showed that dabigatran etexilate capsules performed better than warfarin in reducing the occurrence of stroke and systemic embolism at two doses of 110 mg and 150 mg. Furthermore, the risk of bleeding may be better controlled in patients taking dabigatran etexilate compared with warfarin.

2. Treatment of deep vein thrombosis and pulmonary embolism: RE-COVER (Randomized Evaluation of Long-term Anticoagulation Therapy) and RE-COVER II trials studied the effect of dabigatran etexilate capsules in the treatment of deep vein thrombosis and pulmonary embolism. The results showed that compared with traditional anticoagulant drugs such as warfarin, dabigatran etexilate capsules showed similar or even better effects in the treatment of deep vein thrombosis and pulmonary embolism. In the RE-COVER trial, the risk of recurrent deep vein thrombosis and pulmonary embolism in the short term was significantly reduced in the group of patients treated with dabigatran etexilate capsules compared with the group using warfarin.

3. Postoperative anticoagulation: For some patients who require surgery, especially those undergoing high-risk surgery such as joint replacement surgery, the use of dabigatran etexilate capsules has also been studied in terms of postoperative anticoagulation. RE-NOVATE and RE-NOVATE IIThe trial found that after joint replacement surgery, the use of dabigatran etexilate capsules compared with traditional anticoagulant drugs, such as low-molecular-weight heparin, can reduce the patient's risk of bleeding while maintaining appropriate anticoagulation levels.

The data from these clinical trials support the effectiveness and relatively good safety profile of dabigatran etexilate capsules in anticoagulant therapy. However, patients should still pay close attention to their doctor's advice when using dabigatran etexilate capsules and conduct regular monitoring to ensure that the risk of adverse reactions and bleeding is minimized while minimizing the risk of blood clots.

Dabigatran etexilate capsules have been launched in China and have been included in medical insurance. Patients can purchase them domestically. Please consult the local hospital pharmacy for specific prices. The main foreign drug is the original drug of dabigatran etexilate capsules. The cheaper one is the Turkish version of the original drug from Germany. The price of 110mg*60 capsules is about three to four hundred, and the ingredients and efficacy are consistent with the original drug on the domestic market.